Studies have shown that PDE4 inhibitors can inhibit the release of fibrogenic factors and alleviate pulmonary fibrosis in a mouse model induced by bleomycin (Cortijo et al., 2009; Udalov et al., 2010; Milara et al., 2015). Here, PDE4A is linked to pulmonary fibrosis.